Pharmaceutical business Amerigen Pharmaceuticals Limited revealed on Thursday the receipt of approval from the US Food and Drug Administration for the Abbreviated New Drug Application (ANDA) for the generic version of Adderall XR in 5 mg, 10 mg, 15 mg, 20 mg, 25 mg and 30 mg.
The company has received the US FDA's NDA approval for the generic version of Shire's Adderall XR (dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfate, extended-release capsules) in 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, and 30 mg.
In conjunction, the company's Amerigen Pharmaceuticals Inc US affiliate is currently selling an authorized generic version of Adderall XR, with a planned launch in the near future.
Additionally, the US regulatory and commercial activities within the group are conducted by Amerigen Pharmaceuticals Inc, based in Lyndhurst, NJ.
Fresenius Kabi Introduces Leucovorin Calcium Injection, USP
FDA Approves Dr. Reddy's Tosymra 10 mg, in the US Market
Dr. Reddy's Laboratories Announces the Launch of Propofol Injectable Emulsion, USP in the US Market
Amerigen awarded US FDA's approval for generic mixed amphetamine salts, extended-release capsules
Pharmaceutics International names new president and CEO
Amneal wins US FDA approval for Rivastigmine Transdermal System
Premier Expands Effort to Supply Shortage Generic Drugs
Ferring Pharmaceuticals Adds Two Products to its Reproductive Health Portfolio in the US
China's Bio-Thera Solutions Partners with Cipla to Market Key Cancer Biosimilar
EpicGenetics Moves into New Facility, Expanding Capacity by 4X
Amneal Pharmaceuticals appoints David A. Buchen as SVP, chief legal officer and corporate secretary
Ironwood Pharmaceuticals and Allergan reach agreement to resolve Mylan LINZESS patent litigation
Teva and Amgen Resolve Ongoing Dispute Over Teva's Generic Cinacalet HCl Product